Drug delivery to the back of the eye following topical administration: An update on research and patenting activity

Recent Patents on Drug Delivery and Formulation

Volumn 8, Issue 1, 2014, Pages 27-36

  Boddu, Sai H S ^a   Gupta, Himanshu ^a   Patel, Soohi ^a  

^a UNIVERSITY OF TOLEDO   (United States)

Author keywords

Drug delivery; Eye drops; Posterior segment; Retinal diseases

Indexed keywords

AGENTS ACTING ON THE EYE; BETAXOLOL; BRIMONIDINE; BRINZOLAMIDE; BROMFENAC; DEXAMETHASONE; DIFLUPREDNATE; DORZOLAMIDE; EYE DROPS; HESPERETIN; HESPERIDIN; INULIN; MECAMYLAMINE; MOXAVERINE; NANOCARRIER; NIPRADILOL; OT 551; TANDOSPIRONE; TIMOLOL; UNCLASSIFIED DRUG; VOCLOSPORIN;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; HUMAN; LIPOPHILICITY; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TISSUE DISTRIBUTION; INTRAOCULAR DRUG ADMINISTRATION; PATENT; PROCEDURES; RETINAL DISEASES; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, OPHTHALMIC; ADMINISTRATION, TOPICAL; DRUG DELIVERY SYSTEMS; HUMANS; OPHTHALMIC SOLUTIONS; PATENTS AS TOPIC; RETINAL DISEASES;

EID: 84900547141     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872211308666140130093301     Document Type: Review

References (76)

1. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009; 26(5): 1197-216.
2. Kaplan HJ. Anatomy and function of the eye. Chem Immunol Allergy 2007; 92: 4-10.
3. Wade NJ. Image, eye, and retina (invited review). J Opt Soc Am A Opt Image Sci Vis 2007; 24(5): 1229-49.
4. Knop E, Knop N. Anatomy and immunology of the ocular surface. Chem Immunol Allergy 2007; 92: 36-49.
5. Newell FW. Ophthalmology, principles and concepts. 5th ed. St. Louis: Mosby 1982, 559 p.
6. Ranta V-P, Mannermaa E, Lummepuro K, Subrizi A, Laukkanen A, Antopolsky M, et al. Barrier analysis of periocular drug delivery to the posterior segment. J Controlled Release 2010; 148(1): 42-8.
7. Rhee DJ, Peck RE, Belmont J, Martidis A, Liu M, Chang J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006; 90(8): 999-1003.
8. Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol 2005; 40(1): 63-8.
9. Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006; 141(4): 629-37.
10. Jonas JB. Intravitreal triamcinolone acetonide: A change in a paradigm. Ophthalmic Res 2006; 38(4): 218-45.
11. Sanborn GE, Anand R, Torti RE, Nightingale SD, Cal SX, Yates B, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 1992; 110(2): 188-95.
12. Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007; 4(4): 371-88.
13. Maurice DM. Drug delivery to the posterior segment from drops. Surv Ophthalmol 2002; 47 Suppl 1: S41-52.
14. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 2002; 30(4): 421-9.
15. Koevary SB, Nussey J, and Lake S. Accumulation of topically applied porcine insulin in the retina and optic nerve in normal and diabetic rats. Invest Ophthalmol Vis Sci 2002; 43(3): 797-804.
16. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 2001; 108(4): 784-7.
17. Osborne NN, DeSantis L, Bae JH, Ugarte M, Wood JP, Nash MS, et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res, 1999; 69(3): 331-42.
18. Acheampong AA, Shackleton M, Tang-Liu DD, Ding S, Stern ME, Decker R. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res 1999; 18(2): 91-103.
19. Okamura T, Kitamura Y, Uchiyama M, Toda M, Ayajiki K, Toda N. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic. Pharmacology 1996; 53(5): 302-10.
20. Smith S. Basic ocular anatomy. Insight 2008; 33(3): 19-23; quiz 24-5.
21. Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin Drug Deliv 2006; 3(2): 275-87.
22. Boddu SH, Gunda S, Earla R, Mitra AK. Ocular microdialysis: A continuous sampling technique to study pharmacokinetics and pharmacodynamics in the eye. Bioanalysis 2010; 2(3): 487-507.
23. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discovery Today 2008; 13(3, 4): 135-43.
24. Hughes PM, Olejnik O, Chang-Lin J-E, Wilson CG. Topical and systemic drug delivery to the posterior segments. Adv Drug Deliv Rev 2005; 57(14): 2010-32.
25. Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG. Drug delivery to the posterior segment of the eye. Drug Discovery Today 2011; 16(5-6): 270-7.
26. Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv Ophthalmol 1993; 37(6): 435-56.
27. Klotz SA, Penn CC, Negvesky GJ, Butrus SI. Fungal and parasitic infections of the eye. Clin Microbiol Rev 2000; 13(4): 662-85.
28. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, et al. The multidrug transporter P-glycoprotein: A mediator of melanoma invasion. J Invest Dermatol 2008; 128(4): 957-71.
29. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973; 323(3): 466-83.
30. Saha P, Yang JJ, Lee VH. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells. Invest Ophthalmol Vis Sci 1998; 39(7): 1221-6.
31. Maurice DM, Mishima S. Ocular pharmacokinetics, in Handbook of experimental pharmacology. M.L. Sears, Editor, Springer-Verlag: Berlin, New York 1984, 16-119.
32. Chung YB, Han K, Nishiura A, Lee VH. Ocular absorption of Pzpeptide and its effect on the ocular and systemic pharmacokinetics of topically applied drugs in the rabbit. Pharm Res 1998; 15(12): 1882-7.
33. Huang HS, Schoenwald RD, Lach JL. Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. J Pharm Sci 1983; 72(11): 1272-9.
34. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 1997; 38(3): 627-34.
35. Tópica A, De la Conjuntiva P. Ocular drug absorption by topical route. Role of conjunctiva. Arch soc esp oftalmol 2008; 83: 683-6.
36. Kompella UB, Kadam RS, Lee VH. Recent advances in ophthalmic drug delivery. Ther Deliv 2010; 1(3): 435-56.
37. Maurice DM, Mishima S. Ocular Pharmacokinetics, in Pharmacology of the Eye, M. Sears, Editor, Springer:Berlin Heidelberg 1984. 19-116.
38. Chien D-S, Homsy JJ, Gluchowski C, Tang-Liu DD. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit Eyes. Curr Eye Res 1990; 9(11): 1051-9.
39. Maurice DM, Polgar J. Diffusion across the sclera. Exp Eye Res 1977; 25(6): 577-82.
40. Schoenwald RD, Deshpande GS, Rethwisch DG, Barfknecht CF. Penetration into the anterior chamber via the conjunctival/scleral pathway. J Ocul Pharmacol Ther 1997; 13(1): 41-59.
41. Ahmed I, Patton TF. Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int J Pharm 1987; 38(1-3): 9-21.
42. Conroy CW. Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea. J Ocul Pharmacol Ther 1997; 13(5): 465-72.
43. Ahmed I, Patton TF. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest Ophthalmol Vis Sci 1985; 26(4): 584-7.
44. Osborne NN, Wood JP, Cupido A, Melena J, Chidlow G. Topical flunarizine reduces IOP and protects the retina against ischemiaexcitotoxicity. Invest Ophthalmol Vis Sci 2002; 43(5): 1456-64.
45. Kent AR, King L, Bartholomew LR. Vitreous concentration of topically applied brimonidine-purite 0.15%. J Ocul Pharmacol Ther 2006; 22(4): 242-6.
46. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001; 42(3): 688-94.
47. Mizuno K, Koide T, Shimada S, Mori J, Sawanobori K, Araie M. Route of penetration of topically instilled nipradilol into the ipsilateral posterior retina. Invest Ophthalmol Vis Sci 2009; 50(6): 2839-47.
48. Palanki MS, Akiyama H, Campochiaro P, Cao J, Chow CP, Dellamary L. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotria zin-7-yl)phenyl benzoate (TG100801):A topically administered therapeutic candidate in clinical trials for the treatment of agerelated macular degeneration. J Med Chem 2008; 51(6): 1546-59.
49. Tajika T, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther 2011; 27(1): 43-9.
50. Becker U, Ehrhardt C, Schaefer UF, Gukasyan HJ, Kim KJ, Lee VH, et al. Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma. J Ocul Pharmacol Ther 2005; 21(3): 210-6.
51. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-Hour evaluation of the ocular distribution of 14C-Labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther 2008; 24(4): 392-8.
52. Sigurdsson HH, Konrádsdóttir F, Loftsson T, Stefánsson E. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmologica Scandinavica 2007; 85(6): 598-602.
53. Loftsson T, Hreinsdóttir D, Stefansson E. Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: Aqueous dexamethasone eye drops. J pharmacy pharmacol 2007; 59(5): 629-35.
54. Loftsson T, Sigurdsson HH, Hreinsdottir D, Stefánsson E. Dexamethasone delivery to posterior segment of the eye. J Inclusion Phenomena Macrocyclic Chem 2007; 57(1-4): 585-9.
55. Martinez A, Sanchez-Salorio M. A comparison of the long-term effects of dorzolamide 2% and brinzolamide 1%, each added to timolol 0.5%, on retrobulbar hemodynamics and intraocular pressure in open-angle glaucoma patients. J Ocul Pharmacol Ther 2009; 25(3): 239-48.
56. Kadam RS, Jadhav G, Ogidigben M, et al. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: Implications for effects on ocular blood flow. Drug Metabol Dispos 2011; 39(9): 1529-37.
57. Jansook P, Stefánsson E, Thorsteinsdóttir M, Sigurdsson BB, Kristjánsdóttir SS, Bas JF, et al. Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: Formulation of dorzolamide eye drop microparticle suspension. Eur J Pharm Biopharm 2010; 76(2): 208-14.
58. Srirangam R, Hippalgaonkar K, Avula B, Khan IA, Majumdar S. Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin. J Ocul Pharmacol Ther 2012; 28(6): 618-27.
59. Chen Q, Zheng Y, Li Y, Zeng Y, Kuang J, Hou S, et al. The effect of deacetylated gellan gum on aesculin distribution in the posterior segment of the eye after topical administration. Drug Delivery 2012; 19(4): 194-201.
60. Velagaleti P, Anglade E, Khan J, Gilger BC, Mitra AK. Topical delivery of hydrophobic drugs using a novel mixed nanomicellar technology to treat diseases of the anterior & posterior segments of the eye. Drug Deliv Technol 2010; 10(4): 42-7.
61. Earla R, Boddu SH, Cholkar K, Hariharan S, Jwala J, Mitra AK. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids--quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2010; 52(4): 525-33.
62. Williams KA, Brereton HM, Farrall A, Standfield SD, Taylor SD, Kirk LA, et al. Topically applied antibody fragments penetrate into the back of the rabbit eye. Eye (Lond) 2005; 19(8): 910-3.
63. Thiel MA, Coster DJ, Standfield SD, Brereton HM, Mavrangelos C, Zola H, et al. Penetration of engineered antibody fragments into the eye. Clin Exp Immunol 2002; 128(1): 67-74.
64. Furrer E, Berdugo M, Stella C, Behar-Cohen F, Gurny R, Feige U, et al. Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-?? single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci 2009; 50(2): 771-8.
65. Matier, W.L.H.D.E., Patil, G.L.U.P.A. Amelioration of the development of cataracts and other ophthalmic diseases. US7442711 (2008).
66. Tanito M, Li F, Anderson RE. Protection of retinal pigment epithelium by OT-551 and its metabolite TEMPOL-H against lightinduced damage in rats. Exp Eye Res 2010; 91(1): 111-4.
67. Zhou J, Jang YP, Chang S, Sparrow JR. OT-674 suppresses photooxidative processes initiated by an RPE lipofuscin fluorophore. Photochem Photobiol 2008; 84(1): 75-80.
68. Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, et al. Treatment of geographic atrophy by the topical administration of OT-551: Results of a phase II clinical trial. Invest Ophthalmol Vis Sci 2010; 51(12): 6131-9.
69. Zhang, X.S.C.A., Kengatharan, M.M.P.C.A., Cooke, J.P.P.A.C.A., Takruri, H. Topical mecamylamine formulations for ocular administration and uses thereof. US20070167526 A1 (2007).
70. Feinstein, E.R., Kaufmann, J.B., and Giese, K.B. Methods of treating eye diseases in diabetic patients. US8168607 (2012).
71. Rekik, R.A.d.J.B.M.T. Drug delivery to the anterior and posterior segments of the eye using eye drops. WO2009112878 A1 (2009).
72. Chowhan, M.A.A.T.X., Han, W.W.A.T.X., and Schneider, L.W.C.T.X. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye. US20100160342 A1 (2010).
73. Earla R, Boddu SH, Cholkar K, Hariharan S, Jwala J, Mitra AK. Development and validation of a fast and sensitive bioanalytical method for the quantitative determination of glucocorticoids-Quantitative measurement of dexamethasone in rabbit ocular matrices by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2010; 52(4): 525-33.
74. Mitra, A.K.O.P.K.S., Velagaleti, P.R.R.N.J., and Grau, U.M.N.Y.N.Y. Topical Drug Delivery Systems for Ophthalmic Use. US20100310642 A1 (2010).
75. Kompella, U.B.O.N.E., Singh, S.R.O.N.E., and Sundaram, S.O.N.E. Methods and compositions for targeted delivery of therapeutic agents. US20090087494 A1 (2009).
76. Loftsson, T.R. and Stefansson, E.R. Cyclodextrin nanotechnology for ophthalmic drug delivery. US20070020336 A1 (2007).